Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?

Breast Cancer Res. 2010 Dec 20;12 Suppl 4(Suppl 4):S18. doi: 10.1186/bcr2747.

Author

Kathleen I Pritchard¹

Affiliation

¹ Sunnybrook Odette Cancer Centre, Toronto, Ontario M4N 3M5 Canada. Kathy.Pritchard@sunnybrook.ca

PMID: 21172080
PMCID: PMC3005738
DOI: 10.1186/bcr2747

No abstract available

MeSH terms

Antidepressive Agents, Second-Generation / adverse effects*
Antineoplastic Agents, Hormonal / metabolism*
Antineoplastic Agents, Hormonal / therapeutic use
Breast Neoplasms / drug therapy*
Breast Neoplasms / metabolism
Breast Neoplasms / mortality*
Cytochrome P-450 CYP2D6 / genetics
Cytochrome P-450 CYP2D6 / metabolism
Cytochrome P-450 CYP2D6 Inhibitors
Drug Interactions
Female
Humans
Receptors, Estrogen / analysis
Selective Serotonin Reuptake Inhibitors / adverse effects*
Serotonin Antagonists / adverse effects*
Tamoxifen / metabolism*
Tamoxifen / therapeutic use

Substances

Antidepressive Agents, Second-Generation
Antineoplastic Agents, Hormonal
Cytochrome P-450 CYP2D6 Inhibitors
Receptors, Estrogen
Serotonin Antagonists
Serotonin Uptake Inhibitors
Tamoxifen
Cytochrome P-450 CYP2D6